Literature DB >> 3929577

[Sequential intravesical chemotherapy with mitomycin C and adriamycin for superficial bladder tumor (preliminary report)].

I Fukui, H Sekine, T Yamada, K Kihara.   

Abstract

Intravesical chemotherapy with sequential instillation of mitomycin C and adriamycin was carried out on 19 patients with superficial bladder cancer (Ta, T1 and Tis). Twenty milligram of mitomycin C on day 1 and 40 mg of adriamycin on day 2 were instilled into the bladder, this treatment being repeated weekly for 5 consecutive weeks if there were no serious side effects. The following results were obtained. Of 16 evaluable patients, 10 patients (63%) achieved complete response and 2 patients achieved partial response, 4 patients showing no response. In patients with high grade tumor, especially with carcinoma in situ, a high CR rate (6/7 or 86%) was achieved. Chemical cystitis occurred in 10 out of 19 (53%) patients. In 5 of the 6 patients who suffered from severe cystitis symptoms, treatment was discontinued. However, the symptoms resolved within 4 weeks in all patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929577

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

1.  Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.

Authors:  I Fukui; H Sekine; K Kihara; T Yamada; T Kawai; M Washizuka; D Ishiwata; K Oka; K Hosoda; S Ikegami
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.

Authors:  I Fukui; K Kihara; H Sekine; Y Tachibana; T Kawai; D Ishiwata; H Oshima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer.

Authors:  S Isaka; T Okano; K Abe; J Shimazaki
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.